Worcester drug discovery firm Generex Biotechnology Corp. has named Mark Fletcher as CEO and interim president, replacing Generex co-founder, CEO, president and chairman Anna Gluskin.
“The board has concluded…that Generex has reached a stage in its maturation where new senior management leadership is now needed for the company to capitalize more effectively on the opportunities that we believe are available to the company,” said John Barratt, an independendent director appointed to the chairman role, in a press release. “We believe that a tighter focus on the company’s core business is needed and we have determined that this can only be achieved under a new president and CEO.”
